Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE
Parliamentary submission

DATE
2016-10-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legislation, Regulation and Restriction of Access to Marijuana

Government of Canada - Task Force on Marijuana Legislation and Regulation

August 25, 2014

STATEMENT | DÉCLARATION

CMA Statement - Legislation of Marijuana

Our recommendation: The CMA recommends that the federal government implement a comprehensive policy framework that includes the following:

1. Regulation of marijuana production, distribution, and sale.
2. Legalization of marijuana for medical and non-medical purposes.
3. Public health measures to prevent use among youth and adults.
4. Education and awareness campaigns about the risks and benefits of marijuana use.
5. Research into the impacts of marijuana legalization on public health and social issues.

For more information, please visit the following websites:

- Health Canada: https://www.canada.ca
- Canadian Medical Association: https://www.cma.ca
- Canadian Drug Policy Coalition: https://www.cdpc.ca

The CMA urges all levels of government to work together to ensure that any changes to marijuana laws are evidence-based, scientifically informed, and in the best interests of public health.
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE
Response to consultation

DATE
2016-01-20

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents